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While enteroviruses have been the most commonly
identified cause of aseptic meningitis in the United States,
the role of the emerging, neurotropic West Nile virus (WNV)
is not clear. In summer 2001, an aseptic meningitis epidem-
ic occurring in an area of a WNV epizootic in Baltimore,
Maryland, was investigated to determine the relative contri-
butions of WNV and enteroviruses. A total of 113 aseptic
meningitis cases with onsets from June 1 to September 30,
2001, were identified at six hospitals. WNV immunoglobu-
lin M tests were negative for 69 patients with available
specimens; however, 43 (61%) of 70 patients tested
enterovirus-positive by viral culture or polymerase chain
reaction. Most (76%) of the serotyped enteroviruses were
echoviruses 13 and 18. Enteroviruses, including previously
rarely detected echoviruses, likely caused most aseptic
meningitis cases in this epidemic. No WNV meningitis
cases were identified. Even in areas of WNV epizootics,
enteroviruses continue to be important causative agents of
aseptic meningitis.
W
hen national surveillance for aseptic meningitis was
conducted in the United States, the Centers for
Disease Control and Prevention (CDC) received reports of
7,000 to 14,000 cases of aseptic meningitis per year from
1984 to 1994 (1). Enteroviruses are the leading identifiable
cause of aseptic meningitis in children and adults, particu-
larly in summer and autumn (2). In smaller proportions,
mumps virus (primarily in studies before 1980), her-
pesviruses, lymphocytic choriomeningitis virus, arbovirus-
es, Leptospira, and many other viral and nonviral agents
have been identified in etiologic studies of aseptic menin-
gitis in the United States (3,4). However, the epidemiolo-
gy of aseptic meningitis is not static and, with the appear-
ance of emerging infectious agents such as West Nile virus
(WNV), warrants periodic reevaluation. 
WNV infection is usually asymptomatic but may cause
a wide range of syndromes including nonspecific febrile
illness, meningitis, and encephalitis. In recent WNV epi-
demics in which neurologic manifestations were promi-
nent (Romania, 1996 [5]; United States, 1999–2000 [6,7];
and Israel, 2000 [8]), meningitis was the primary manifes-
tation in 16% to 40% of hospitalized patients with WNV
disease. However, because WNV meningitis has nonspe-
cific clinical manifestations and requires laboratory testing
for a definitive diagnosis, case ascertainment and testing
practices can affect the number of cases diagnosed.
Because WNV testing in U.S. surveillance programs has
focused on patients with encephalitis of undetermined
cause (9), the role of WNV as a cause of aseptic meningi-
tis in the United States is not clear. 
A 2001 investigation in Baltimore provided an oppor-
tunity to evaluate the role of WNV in the epidemiology of
aseptic meningitis and to assess WNV surveillance. From
Baltimore City and County, 118 cases of aseptic meningi-
tis with onsets from June 1 to September 30, 2001, were
reported to Maryland’s Department of Health and Mental
Hygiene (DHMH), compared to an average of 39 cases
during the same summer season in 1997–2000.
Approximately 95% of these 2001 cases were reported
without known cause. Simultaneously, an intense WNV
epizootic among birds was detected in the Baltimore area
(288 WNV-infected dead birds and 14 WNV-infected
mosquito pools were collected before September 30,
2001). Early in the summer, nearly 100% of dead crows
collected from some sections of Baltimore City tested
positive for WNV. When the investigation of aseptic
meningitis was initiated in mid-September, one case of
human WNV encephalitis had been reported from
Baltimore. The investigation’s objectives included 1)
identification of the predominant cause(s) of the aseptic
meningitis epidemic, emphasizing the relative contribu-
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Methods
Discharge Diagnoses Code Review
To confirm an increase in aseptic meningitis cases by a
method independent of case reporting to DHMH, a dis-
charge diagnosis code review was conducted at the six
investigation hospitals. Included were patients with aseptic
meningitis (including International Classification of
Diseases [ICD]-9-CM codes 047.0, 047.1, 047.8, 047.9,
049.0, 049.1, 053.0, 054.72, 072.1) who were evaluated
from June 1 to September 30, 1998–2001. 
Case Definitions
The investigation was conducted at six hospitals that
collectively reported to DHMH 76% of the 118 aseptic
meningitis cases from Baltimore City and County. A case
of aseptic meningitis was defined as an illness with onset
from June 1 to September 30, 2001; cerebrospinal fluid
(CSF) cell count of >5 leukocytes per milliliter; negative
CSF bacterial cultures; and no physician or laboratory doc-
umentation of bacterial, fungal, or parasitic central nerv-
ous system (CNS) disease, cerebral hemorrhage, carcino-
matous meningitis, or cerebral vasculitis. Neonates who
developed CSF abnormalities before first hospital dis-
charge were excluded, as were persons with a physician-
documented diagnosis of encephalitis, confusion, or
obtundation. A case of enteroviral meningitis was defined
as an illness meeting the criteria for aseptic meningitis and,
in addition, a positive enterovirus culture of a CSF, rectal
swab, or nasopharyngeal specimen, or a positive
enterovirus polymerase chain reaction (PCR) test of a CSF
specimen. Acase of WNVmeningitis was defined as an ill-
ness meeting the criteria for aseptic meningitis and, in
addition, WNV immunoglobulin (Ig) M detected in a CSF
specimen by enzyme-linked immunosorbent assay
(ELISA), a greater than-four-fold rise of WNV-neutraliz-
ing antibodies in acute- and convalescent-phase serum
specimens, or WNV nucleic acid detected in a CSF speci-
men by PCR. The investigation was limited to persons liv-
ing in Baltimore City or County who were evaluated at one
of the six investigation hospitals.
Case Ascertainment
Cases reported to DHMH as the code “viral meningitis”
were reviewed. Depending on the resources of each hospi-
tal, additional cases were identified by computerized
queries for test results of >5–10 leukocytes per milliliter in
CSF, and by review of hospital discharge diagnoses codes.
For each case, a standardized form was used to abstract
clinical information from the medical record.
Acute-Phase and Convalescent-Phase 
Specimens and Interviews
Acute-phase (<8 days after illness onset) CSF, serum,
rectal swab, and nasopharyngeal specimens were collected
if ordered by the patients’ physicians. Specimens were
stored at hospital, DHMH, or private reference laboratories
at temperatures ranging from 4°C to –70°C. During home
visits to consenting patients >12 years of age who had had
aseptic meningitis of unknown cause, convalescent-phase
(>7 days after illness onset) blood specimens were collect-
ed and a standardized questionnaire was administered to
characterize symptoms and duration of illness.
Diagnostic Testing
Hospitals performed routine cell counts, chemistries,
and bacterial cultures of CSF for patients with sufficient
specimen quantity. Some patients’ physicians ordered
additional tests. These tests commonly included, for CSF
specimens, latex agglutination screening tests for bacterial
antigens, culture or PCR tests for enteroviruses or her-
pesviruses, and culture for fungi; for CSF or serum speci-
mens,  Borrelia burgdorferi antibody, Venereal Disease
Research Laboratory test, and cryptococcal antigen test;
and for nasopharyngeal and rectal swab specimens, culture
for enteroviruses. 
For available specimens from patients with aseptic
meningitis of unknown cause, arbovirus serologic testing
was performed at DHMH laboratories, and WNV PCR
tests were completed at DHMH laboratories or the
Division of Vector-Borne Infectious Diseases, CDC. CSF
specimens were tested by ELISA for IgM antibodies to
WNV and by TaqMan reverse transcriptase (RT-) PCR
tests for WNV (10,11). Serum specimens were tested at
DHMH laboratories by ELISA for IgM antibodies to
WNV, and by immunofluorescence assay (IFA) for IgM
and IgG antibodies to La Crosse, St. Louis encephalitis,
eastern equine encephalomyelitis, and western equine
encephalomyelitis viruses. 
Available CSF and rectal swab specimens from patients
with aseptic meningitis of unknown cause were tested by
enterovirus culture at the Respiratory and Enteric Viruses
Branch, CDC. Three cell lines were used at CDC for
enterovirus culture: RD (human rhabdomyosarcoma),
HELF (human embryonic lung fibroblast), and LLC-MK2
(monkey kidney). Isolates were serotyped by RT-PCR
amplification and subsequent sequencing of an approxi-
mately 320-nt segment of the VP1 enterovirus gene (12).
When available, enteroviruses already isolated by hospital
laboratories from CSF, nasopharyngeal, or rectal swab
specimens were serotyped by CDC.
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To evaluate strategies used to diagnose WNV meningi-
tis in Maryland, reporting and testing policies were
reviewed. Information was obtained from DHMH case-
reports, surveillance plans and summaries, and laboratory
tests of investigation patients.
Results
Confirmation of an Epidemic by 
Discharge Diagnosis Review
Each summer season (June 1–September 30) of
1998–2000, an average of 67 Baltimore residents were
evaluated at the six investigation hospitals and assigned an
aseptic meningitis ICD-9-CM code; in the 2001 season,
133 persons were evaluated, a 99% increase above the
1998–2000 seasonal average (Figure 1). At one of the
investigation hospitals, the specificity of ICD-9-CM codes
was assessed. A medical record review showed that 23
(96%) of 24 cases identified by ICD-9-CM codes met the
investigation’s case definition of aseptic meningitis.
Cases
At the six investigation hospitals, 113 aseptic meningi-
tis patients were identified with illness onsets from June 1
to September 30, 2001. By the week of illness onset, the
number of cases peaked in late August and early
September (Figure 2). The median patient age was 18
years (range 1 week–74 years of age), and 56% of patients
were male. Seventy-eight percent of patients were med-
ically evaluated within the first 3 days after illness onset.
Of the 110 patients with available information, the median
duration of hospitalization was 2 days (range 0–11 days).
No fatalities occurred during hospitalization nor were any
subsequently reported to DHMH.
The median CSF leukocyte count was 135/mL (range
7–1,083/mL). Of the 110 patients with available data, 45
(41%) had >50% polymorphonuclear cells in CSF leuko-
cyte count, including 9 (43%) of 21 patients who had CSF
collected 4–10 days after illness onset. CSF glucose was
normal (≥40 mg/dL) in 99% of patients (n=110), and CSF
protein was elevated (>50 mg/dL) in 52% (n=111: median
53 mg/dL; range 10–215 mg/dL) (Table 1).
On the basis of standardized interviews of 33 patients
(median age, 31 years; range 13–55 years of age) at the
time convalescent-phase blood specimens were obtained,
the most commonly reported acute-phase symptoms were
headache (100%), fever (85%), and eye pain or sensitivity
to light (85%). Illness was sometimes prolonged by per-
sistent fatigue and headaches. The median duration of ill-
ness was 18 days (n=32; range 5–47 days). Twelve of the
patients had not fully recovered by the time of interview;
for these patients, the duration of illness was defined as
(date of interview) – (date of illness onset). Patients ≥18
years of age reported longer duration of symptoms (n=24;
median duration 22 days) than patients 13-17 years of age
(n=8; median duration 7 days) (p=0.001, Kruskal-Wallis
test of significance in Epi-Info 6 software).  
WNV Test Results 
Of the 69 patients for whom at least one ELISA WNV
IgM test was performed on CSF or serum, none tested pos-
itive. Of these 69, ELISAWNV IgM testing was performed
on both acute- and convalescent-phase specimens for 23
patients, on only acute-phase specimens for 36 patients, and
on only convalescent-phase specimens for 10 patients.
Arboviral IgM IFAs completed on acute- or convalescent-
phase serum specimens from 39 patients were all negative.
WNV PCR tests completed on acute-phase CSF specimens
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Figure 1. Residents of Baltimore City and County evaluated at six
hospitals and assigned aseptic meningitis ICD-9-CM discharge
diagnosis codes
a during June 1–September 30, 1998–2001. 
aIf
during one season a patient had >1 discharge diagnosis codes for
aseptic meningitis, the patient was only counted once. 
Figure 2. Aseptic meningitis cases* by week of illness onset, June
1–September 30, 2001, identified at six hospitals, Baltimore,
Maryland. *N=112 (illness onset date missing for one patient);
Coxsackievirus B2 = “CB2”; Echovirus 6 = “E6”, Echovirus 13 =
“E13”; Echovirus 18 = “E18”; Echovirus 30 = “E30”.from 27 patients were also negative. Acute-phase speci-
mens were collected <8 days after illness onset, and conva-
lescent-phase specimens were collected a median of 40
days after illness onset (range 12–111 days); exact dates
were not available for two patients.
Enterovirus Test Results
Of 70 patients who had at least one test (viral culture or
PCR test) performed for enteroviruses, 43 (61%) patients
were confirmed to have enteroviral meningitis. Among
patients who had at least one enterovirus test performed,
the percentage enterovirus-positive was highest in infants
and children; however, of 30 tested patients >18 years of
age, 13 (43%) were enterovirus-positive (Table 2). Of the
34 cases in which enterovirus serotyping was completed,
five serotypes were identified. Echovirus 13 (15 cases) and
echovirus 18 (11 cases) together accounted for 76% of the
serotyped isolates (Table 1).
Other Diagnoses 
Two patients were diagnosed with herpes simplex virus
meningitis by culture-positive CSF specimens, and one
patient was diagnosed with Lyme meningitis on the basis
of clinical signs and symptoms of acute facial palsy and
meningitis, and positive serum B. burgdorferi antibody by
ELISA and Western blot tests.
Sixty-seven (59%) of the 113 patients in the investiga-
tion remained undiagnosed; for many, sufficient specimens
did not exist for further testing. The median age of these
undiagnosed patients was 25 years, and 61% were male.
Duration of hospitalization was similar to the cases with
known cause. Five of the undiagnosed patients had HIV
infection, and another four had a history of prior meningi-
tis. Twenty-seven (40%) of the undiagnosed patients had at
least one enterovirus test (culture or PCR) performed.
Forty-six (68%) of the undiagnosed patients, including 24
with convalescent-phase specimens collected a median of
44 days after illness onset (exact dates not available for
two patients) (range 12–111 days), had at least one WNV
IgM ELISA performed. To estimate the number of WNV
meningitis cases that could have been missed, we assumed
that these 24 patients represented a random sample of the
67 undiagnosed patients, and that WNV infection was
ruled out in patients with a negative result from a WNV
IgM ELISAperformed on a convalescent-phase serum. On
the basis of these assumptions, 0% (95% confidence inter-
val 0% to 10%) WNV IgM positivity among the sample
suggests that fewer than seven cases of WNV meningitis
were missed among the investigation patients.
Evaluation of Aseptic Meningitis and WNV Surveillance
Human WNV surveillance in Maryland focused on
patients with two reportable CNS infections, encephalitis
or aseptic meningitis, of unknown cause. Of the 113 asep-
tic meningitis cases identified at the six investigation hos-
pitals, 76 (67%) had been reported to DHMH. Of these 76
aseptic meningitis cases, 71 (93%) were reported without
a cause. Because of the urgency to detect WNV epidemics,
WNV serologic testing was the first-line test conducted by
DHMH laboratories for patients with aseptic CNS infec-
tions of unknown cause. WNV testing was first prioritized
for patients with encephalitis, and secondarily for hospital-
ized patients with aseptic meningitis who were >17 years
of age (late in the season, this last criteria was expanded to
>5 years of age). During 2001, DHMH laboratories con-
ducted WNV testing for 440 patients statewide (including
approximately 230 patients reported with aseptic meningi-
tis); 6 patients were diagnosed with WNV disease. 
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Table 1. Descriptive summary of aseptic meningitis cases with onsets from June 1 to September 30, 2001, identified at six hospitals, 
Baltimore, Maryland
a 
CSF 
Cause  Cases 
Median age 
(range) 
% <18 y  
of age 
Median leukocyte 
count/mL (range) 
% PMN 
predominant 
Median protein 
mg/dL (range) 
All enterovirus meningitis cases  43  9 y (1 wk–49 y)  70  178 (10–850)  49  48 (10–215) 
 Echovirus  13    15  7 y (1 mo–49 y)  87  132 (11–650)  80  37 (18–97) 
 Echovirus  18  11  17 y (2 mo–35 y)  55  173 (12–409)  27  44 (16–215) 
 Coxsackievirus  B2  5  19 y (1 wk–31 y)  40  250 (45–850)  0  87 (57–120) 
 Echovirus  6  2  33 y (31–34 y)  0  330 (130–530)  50  56 (52–59) 
 Echovirus  30  1  10 y  1  10  0  18 
 Untyped  enterovirus  9  9 y (1 mo–20 y)  89  178 (43–850)  56  48 (10–153) 
Herpes simplex virus meningitis cases  2  39 y (29–49 y)  0  246 (136–355)  0  128 (77–179) 
Lyme meningitis case  1  74 y  0  227  0  143 
Cases of undetermined cause  67  25 y (2 wk–67 y)  39  100 (7–1083)  38
b  53
c (19–209) 
Total cases  113  18 y (1 wk–74 y)  50  135 (7–1083)  41
d  53
e(10-215) 
aCSF, cerebrospinal fluid; PMN, polymorphonuclear cells.  
bN=64. 
cN=65. 
dN=110.  
eN=111. DHMH requested CSF, acute-, and convalescent-phase
serum specimens for the diagnosis of WNV infection.
However, before the investigation, essentially only acute-
phase specimens (CSF more frequently than serum) from
Baltimore patients were tested by WNV serologic tests;
routine collection of convalescent-phase serum specimens
was not feasible.
Enterovirus testing was not a component of DHMH
aseptic meningitis surveillance. If enterovirus testing was
initiated by the hospital, positive results were often not
communicated to DHMH laboratories. Of 69 patients for
whom at least one WNV IgM test was performed by
DHMH, enteroviral meningitis was subsequently diag-
nosed in 23 (50% of 46 for whom at least one enterovirus
culture or PCR test was performed).
Discussion
Although enhanced WNV surveillance among persons
with aseptic meningitis could have been partially responsi-
ble for the tripling of Baltimore case-reports of aseptic
meningitis during the summer of 2001, trends in discharge
diagnosis codes suggest that a true increase in aseptic
meningitis cases occurred. Despite a concurrent, intense
WNV epizootic among birds, no evidence existed that
WNV substantially contributed to the aseptic meningitis
epidemic. By routine surveillance, five WNV encephalitis
cases but no WNV meningitis cases were ultimately
detected in Baltimore in 2001. However, in this setting, the
five recognized WNV encephalitis cases did not appear to
represent large numbers of undiagnosed WNV meningitis
cases. Surveillance conducted in other states has also sug-
gested that intense WNV epizootic activity does not neces-
sarily correlate with large numbers of human WNV CNS
infections (13). 
Instead, multiple enterovirus serotypes likely caused
most of the Baltimore aseptic meningitis cases. This find-
ing is consistent with population-based studies (14–16)
and large outbreak investigations (17,18) of aseptic menin-
gitis occurring during the summer and fall in the United
States. However, unlike outbreak investigations of the past
few decades, echovirus 13 and echovirus 18 were the most
commonly isolated agents in this investigation and might
have accounted for the increased number of aseptic menin-
gitis cases in Baltimore. Echovirus 13 was previously
rarely detected in the United States. From 1970 to 2000,
only 65 of 45,000 enterovirus isolates reported to CDC
were echovirus 13 (19). Echovirus 18 had been relatively
quiescent for over a decade; from 1988 to 2000, only 200
isolates were reported to CDC (20). In a study conducted
from 1986 to 1990 in Baltimore hospitals among infants
<2 years of age who were hospitalized with aseptic menin-
gitis, only one case of echovirus 13 and two cases of
echovirus 18 (among 167 serotyped enterovirus isolates)
meningitis were identified (14). 
In 2001, the previously rarely detected echoviruses 13
and 18 were the two enteroviruses most commonly report-
ed to CDC (20). Multiple states reported echovirus 13 in
association with aseptic meningitis outbreaks, and
Tennessee reported an aseptic meningitis outbreak attrib-
uted to both echovirus 13 and 18 (19). Where previously
rarely detected, echovirus 13 was isolated in association
with aseptic meningitis outbreaks in Australia during 2001
(21) and in the United Kingdom (22) and Germany (23)
during 2000. Surveillance data have previously demon-
strated that in one or two seasons a usually quiescent
serotype may cause an outburst of clinical disease super-
imposed on background, area-endemic enteroviruses (24).
The worldwide spread of epidemics of clinical enteroviral
disease has been documented with other serotypes, includ-
ing echovirus 9 and enterovirus 70 (25). 
Limitations of this study should be acknowledged.
Physicians may have diagnosed more aseptic meningitis in
response to WNV publicity; however, physicians more
likely recognized that the risk and discomfort of a lumbar
puncture required to diagnose meningitis outweighed the
public health interest in identifying an untreatable condi-
tion, WNV meningitis. Regarding the investigation, only
aseptic meningitis cases that could be rapidly identified at
the six Baltimore hospitals were included. Not all patients
underwent the same tests in the same laboratories, and the
quality of enterovirus testing differed because of variable
conditions of specimens. Additional results of other tests
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Table 2. Enterovirus meningitis cases by age group, onsets June 1 to September 30, 2001 identified at six hospitals, Baltimore, Maryland 
Age group (y)  Aseptic meningitis cases  % test-positive
a for enterovirus  (no. test-positive/no. tested for enterovirus) 
<1  12  80 (8/10) 
1–10  24  94 (15/16) 
11–20  29  50 (11/22) 
21–30  11  75 (3/4) 
31–40  26  38 (5/13) 
41–50  5  33 (1/3) 
>50  6  0 (0/2) 
All  113  61 (43/70) 
aThirty-four (79%) of the 43 enterovirus meningitis cases had a positive viral culture or polymerase chain reaction test result of cerebrospinal fluid (CSF) specimens. 
Seven cases had negative CSF tests and were only diagnosed by positive viral culture of nasopharyngeal or rectal swab specimens. Two additional cases did not have 
sufficient CSF available for testing and were diagnosed by positive culture of nasopharyngeal or rectal swab specimens. performed at reference laboratories might have become
available only after the investigation ended. As a result,
although any positive WNV test result would likely have
been reported, the percentage of enterovirus test-positive
cases could be inaccurate. Finally, similar to previous stud-
ies of the epidemiology of aseptic meningitis (2), 59% of
cases remain undiagnosed; another, untested agent may
have caused the increased number of aseptic meningitis
cases in Baltimore. 
The consistent predominance of enteroviruses among
the known causes of aseptic meningitis in children and
adults versus the relative infrequency of WNV meningitis
(even during an intense WNV epizootic) warrants recon-
sideration of WNV surveillance testing strategies. Most
cases of aseptic meningitis were reported to DHMH with-
out a known cause. For these patients, WNV testing was
the first priority to enable early detection of WNV epi-
demics that would warrant additional vector control inter-
ventions. By contrast, enterovirus testing was not a compo-
nent of surveillance among patients with aseptic meningi-
tis. Although no WNV meningitis was identified, >30% of
the patients who underwent WNV testing were later deter-
mined to have had enteroviral meningitis. Many patients
with aseptic meningitis were tested for an apparently rare
virus, WNV, before being tested for the common agents,
enteroviruses. During nonepidemic years, WNV IgM
ELISA may be low yield when performed as a first-line
test for aseptic meningitis. By contrast, enterovirus testing
likely can identify the cause of a large fraction of aseptic
meningitis cases.
The complexities and resource requirements of WNV
serologic testing suggest that other testing strategies need
to be developed. During 2001, DHMH laboratories con-
ducted WNV testing for 440 patients statewide, often per-
forming multiple tests for each patient; 6 patients were
diagnosed with WNV disease. WNV ELISAs require at
least 2–3 days to complete. PCR tests for WNV in CSF
specimens are more rapid but have poor sensitivity (26).
Because patients often seek medical care early after illness
onset when WNV antibodies might not be detectable, sero-
logic tests of specimens collected at the time of first symp-
toms may also have poor sensitivity. Serologic testing of
convalescent-phase serum specimens may be the most sen-
sitive method to detect WNV infection. Yet, collecting
convalescent-phase specimens can be logistically difficult
and, as in Baltimore’s WNV surveillance program, may
not be routinely feasible. When collected through primary
care physicians, billing issues can be problematic, and
each home visit for collection of blood specimens may
require several hours of staff time. 
An improved laboratory-based surveillance strategy
might include a two-stage testing algorithm at hospital or
public health laboratories to evaluate patients with aseptic
meningitis. The goals would be 1) to judiciously use spec-
imens of limited quantity (especially CSF) to rapidly iden-
tify common or treatable causes of aseptic meningitis and
2) to improve the yield of the more complex testing
required to diagnose arboviral disease. 
As a first stage of testing, multiplex PCR tests have been
used to detect enteroviruses, herpes simplex 1 and 2, and
varicella zoster (27,28). Several studies indicate that PCR
tests for enteroviruses (29) and herpes simplex virus (30)
are highly specific, can be completed more rapidly (<6
hours required), require less quantity of CSF, and potential-
ly are more sensitive than traditional cell culture. Using
PCR tests to identify enterovirus infections in patients with
aseptic meningitis can reduce unnecessary ancillary tests
and antibiotic or antiviral therapy and allows shortened
hospitalizations (31). In addition, treatment for enteroviral
infection may become available in the near future (32). 
If no diagnosis is made after completion of screening
tests for common or treatable agents and evidence of
regional WNV or other arbovirus activity exists, a second
stage of testing might include arbovirus IgM ELISA of
acute- and convalescent-phase specimens. To rule out
WNV disease, WNV IgM and WNV IgG ELISAs may
need to be conducted approximately 8–45 days after illness
onset (WNV IgG ELISAs may be complicated by cross-
reactions that can only be differentiated by logistically dif-
ficult plaque reduction neutralization tests) (10). The
importance of the timing of specimen collection should be
clearly communicated to healthcare providers.
The epidemiology of aseptic meningitis and other CNS
infections is not fixed and may vary by location; in the
same location, the epidemiology may vary by different
seasons. For example, while relatively quiescent in most
years, WNV has the potential to cause large epidemics in
humans. Because WNV disease does not have unique clin-
ical manifestations, adequate laboratory testing is the only
way to identify human WNV epidemics. Refinement of
laboratory testing strategies for WNV surveillance may
help build broader public health laboratory capacity for the
diagnosis of arboviral and other CNS infections. 
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